Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708)
- 주제(키워드) Ovarian neoplasms , Histologic subtype , Neoadjuvant therapy , Non-high grade serous carcinoma , Survival
- 주제(기타) Oncology
- 설명문(일반) [Chung, Young Shin; Lee, Jung-Yun] Yonsei Univ, Inst Womens Life Med Sci, Dept Obstet & Gynecol, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea; [Park, Sang-Yoon] Natl Canc Ctr, Ctr Uterine Canc Hosp, 323 Ilsan Ro, Goyang Si 410769, Gyeonggi Do, South Korea; [Park, Jeong-Yeol] Univ Ulsan, Asan Med Ctr, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Lee, Jeong-Won] Sungkyunkwan Univ, Samsung Med Ctr, Dept Obstet & Gynecol, Sch Med, Seoul, South Korea; [Kim, Hee Seung] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Suh, Dong Soo] Pusan Natl Univ, Dept Obstet & Gynecol, Sch Med, Busan, South Korea; [Suh, Dong Soo] Pusan Natl Univ Hosp, Biomed Res Inst, Busan, South Korea; [Kim, Yun Hwan] Ewha Womans Univ, Dept Obstet & Gynecol, Div Gynecol Oncol, Coll Med, Seoul, South Korea; [Lee, Jong-Min] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Kim, Miseon] CHA Univ, CHA Gangnam Med Ctr, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Choi, Min Chul] CHA Univ, Comprehens Gynecol Canc Ctr, CHA Bundang Med Ctr, Seongnam, South Korea; [Shim, Seung-Hyuk] Konkuk Univ, Dept Obstet & Gynecol, Sch Med, Seoul, South Korea; [Lee, Keun Ho] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea; [Song, Taejong] Kangbuk Samsung Hosp, Dept Obstet & Gynecol, Sungkyunkwan Univ, Sch Med, Seoul, South Korea; [Hong, Jin Hwa] Korea Univ, Guro Hosp, Coll Med, Dept Obstet & Gynecol, Seoul, South Korea; [Lee, Won Moo] Hanyang Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Lee, Banghyun] Hallym Univ, Dept Obstet & Gynecol, Kangdong Sacred Heart Hosp, Seoul, South Korea; [Lee, In Ho] Dankook Univ, Coll Med, Cheil Gen Hosp, Dept Obstet & Gynecol, Seoul, South Korea; [Lee, In Ho] Dankook Univ, Coll Med, Womens Healthcare Ctr, Seoul, South Korea
- 등재 SCIE, SCOPUS
- OA유형 Green Published, gold
- 발행기관 BMC
- 발행년도 2019
- URI http://www.dcollection.net/handler/ewha/000000160308
- 본문언어 영어
- Published As http://dx.doi.org/10.1186/s12885-019-5514-7
- PubMed https://pubmed.ncbi.nlm.nih.gov/30971221
초록/요약
Background Outcomes of patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy (NAC) have been widely studied, but there is limited information on the outcomes of patients with non-HGSC. This study aimed to evaluate the outcomes of NAC in non-HGSC patients with advanced-stage ovarian cancer. Methods We conducted a retrospective cohort study of patients who underwent NAC for advanced stage non-HGSC between 2002 and 2017 in 17 institutions. Demographics, surgical outcomes, and survival rates were evaluated according to histological subtypes. Results A total of 154 patients were included in this study, comprising 20 cases (13.0%) of mucinous adenocarcinoma, 31 cases (20.1%) of endometrioid adenocarcinoma, 28 (18.2%) cases of clear cell carcinoma, 29 (18.8%) cases of low-grade serous carcinoma and 12 cases (7.8%) of carcinosarcoma. Complete remission/partial remission after the third cycle of NAC was achieved in 100 (64.9%) patients and optimal debulking surgery (residual disease <= 1cm) at interval debulking surgery was achieved in 103 (66.9%) patients. The most common reason for performing NAC was high tumor burden (n=106, 68.8%). The median progression-free survival (PFS) was 14.3months and median overall survival (OS) was 52.9months. In multivariate analyses, mucinous and clear cell carcinoma were negative prognostic factors for both PFS (p=0.007 and p=0.017, respectively) and OS (p=0.002 and p=0.013, respectively). Conclusions In this study, poor survival outcomes were observed in patients with mucinous and clear cell carcinoma undergoing NAC. Different treatment strategies are urgently required to improve survival outcomes for this disease subset.
more